5 / 30
Reference
Antibodies
N
Pathologists
Findings
Hirsch, FR et al. J Thorac Oncol 2016
(BluePrint)
SP142, SP263, 28-8, 22C3
38
3
SP263, 28-8, 22C3 equivalent in tumor cells; SP142, lower
sensitivity
Ratcliffe, MJ et al. Clin Cancer Res 2017
SP263, 28-8, 22C3
493
1
SP263, 28-8, 22C3 equivalent in tumor cells
Scheel, AH et al. Mod Pathol 2016
SP142, SP263, 28-8, 22C3, E1L3N
30
9
SP263, 28-8, 22C3 equivalent in tumor cells; SP142, lower
sensitivity
Scheel, AH et al. Histopathology 2018
SP142, SP263, 28-8, 22C3, E1L3N , QR1
21
10
SP263, 28-8, 22C3 equivalent; SP142, lower sensitivity; LDT,
variable
Gaule, P et al. JAMA Oncol 2016
SP142, SP263, 28-8, 22C3, E1L3N , 9A11
30
4
E1L3N, SP263, 28-8, 22C3, SP142 equivalent in tumor cells
Rimm, DL et al. JAMA Oncol 2017
SP142, 28-8, 22C3, E1L3N
90
13
SP142<22C3<28-8 & E1L3N
Adam, et al. Ann Oncol 2018
SP263, 28-8, 22C3
41
7
SP263, 28-8, 22C3 equivalent in tumor cells
Batenchuk, C et al. Proc Am Assoc Cancer
Res 2017
28-8, 22C3
158
8
28-8, 22C3 equivalent in tumor cells
Skov, BG et al. Appl Imm Mol Morphol 2017
28-8, 22C3
86
2
28-8, 22C3 equivalent in tumor cells
Yeh, Y etal. Ann Oncol 2016
SP263, SP142, 22C3
219
-
SP142<22C3<SP263
Soo, R et al. J Thorc Oncol 2016
SP142, SP263, 28-8, 22C3
20
-
28-8<SP142<SP263&22C3
Eleven key publications for PD-L1
IHC assay harmonization in NSCLC